Search
Rusfertide
go.drugbank.com/drugs/DB17724ApprovedInvestigationalRusfertide is a hepcidin mimetic used to treat erythrocytosis in adults with polycythemia vera. … [L64098] The FDA approved rusfertide on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer.
rdESAT-6
go.drugbank.com/drugs/DB21906ApprovedrdESAT-6 is a recombinant dimer of _Mycobacterium tuberculosis_ early secretory antigenic target used as an ingredient in the diagnostic agent SIILTIBCY along with [rCFP-10].[L53638]
Synonyms: rdESAT-6Tozinameran
go.drugbank.com/drugs/DB15696ApprovedInvestigational[A225386] Comirnaty was granted a EUA in the UK on December 2, 2020,[L26676] and in Canada on December 9, 2020[L26671] for active immunization against SARS-CoV-2. … Comirnaty is also approved for use as a fourth booster shot in adults 50 years of age and older.[L41350]
Mixtures: Comirnaty Original & Omicron Ba.4/ba.5, Comirnaty Original & Omicron Ba.4/ba.5Givinostat
go.drugbank.com/drugs/DB12645ApprovedInvestigational[L50316,A263446] Givinostat was granted FDA approval in March 2024 for the treatment of patients ≥6 years of age with Duchenne muscular dystrophy (DMD). … Givinostat is a small molecule histone deacetylase (HDAC) inhibitor.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersDeoxycholic acid
go.drugbank.com/drugs/DB03619ApprovedInvestigationalDeoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that … It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical
Mixtures: Debiline HProducts: BELKYRA® SOLUCION INYECTABLE, NOTEMP® SOLUCIÓN ESTERIL INYECTABLE.Sipuleucel-T
go.drugbank.com/drugs/DB06688ApprovedInvestigationalIt must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). … Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers.
Categories: sipuleucel-T, Intercellular Adhesion Molecule-1Synonyms: Sipuleucel-TmRNA-1283
go.drugbank.com/drugs/DB22668ApprovedInvestigational[L53408] It is the primary ingredient in mNEXSPIKE, a COVID-19 mRNA vaccine developed by Moderna. … [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from
Indacaterol
go.drugbank.com/drugs/DB05039ApprovedInvestigationalIt was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. … Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Mixtures: ATECTURA®BREEZHALER®150/80 MCG POLVO PARA INHALACIÓN CÁPSULA DURA, ULTIBRO- BREEZHALER®Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesTrofinetide
go.drugbank.com/drugs/DB06045ApprovedTrofinetide is a novel synthetic analog of [glypromate], also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor … [A258453] Trofinetide is marketed as DAYBUE and DAYBUE STIX in the United States, as DAYBUE in Canada, and as DAYBU in the European Union.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsSynonyms: glycyl-L-2-methylprolyl-L-glutamic acidTrimethadione
go.drugbank.com/drugs/DB00347ApprovedWithdrawnAn anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378)
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-Ring